Introduction
Progression of chronic kidney disease (CKD) toward end-stage renal disease (ESRD) is an unmet biomedical challenge, just like chronic progressive failure of any other parenchymal organ, because effective therapies to target progressive loss of functional parenchymal cells and organ fibrosis are not yet available. While efforts to implement interventional therapeutic regimens failed to treat already established chronic kidney lesions, it has been known for decades that parenchymal organs, including the kidney, can be preconditioned to resist later ensuing tissue injuries, preventing progressive loss of functional epithelium and kidney fibrosis (1) (2) (3) . Based on the organ-spanning effectiveness of preconditioning regimens, we hypothesized that the underlying mechanisms could be utilized to aid the kidney in realizing its endogenous regenerative capacity even after manifestation of chronic kidney lesions.
Among different preconditioning approaches, several independent studies highlighted efficacy of FK506 (synonym, tacrolimus or fujimycin) administration to protect against acute experimental injuries (4) involving various parenchymal organs, including kidney (5), heart (6), liver (7), lung (8), brain (9) , spinal cord (10), skin (11) , and intestine (12) . FK506 is a macrolide calcineurin inhibitor (CNI) that elicits immunosuppression by forming a complex with distinct FK506-binding proteins (FKBPs) to attenuate transcription of proinflammatory cytokines dependent on nuclear factor of activated T cells (NFAT) and NF-κB (13) . FK506 is commonly used to lower risk of rejection after allogeneic organ transplantation, although its clinical utility is limited by its nephrotoxicity (14) . While possible renoprotection by FK506 appears counterintuitive in light of its clinically established nephrotoxicity, effective organ protection was demonstrated at doses far below concentrations required for calcineurin-dependent immunosuppression (picomolar versus nanomolar range) (5) (6) (7) (8) (9) , suggesting involvement of calcineurin-independent and yet-unknown mechanisms. Here, we aim to elucidate molecular mechanisms underlying such protective activity of low-dose FK506 administration and to explore whether this pathway could be utilized even to protect from chronic progressive organ failure.
Progression of chronic kidney disease associated with progressive fibrosis and impaired tubular epithelial regeneration is still an unmet biomedical challenge because, once chronic lesions have manifested, no effective therapies are available as of yet for clinical use. Prompted by various studies across multiple organs demonstrating that preconditioning regimens to induce endogenous regenerative mechanisms protect various organs from later incurring acute injuries, we here aimed to gain insights into the molecular mechanisms underlying successful protection and to explore whether such pathways could be utilized to inhibit progression of chronic organ injury. We identified a protective mechanism controlled by the transcription factor ARNT that effectively inhibits progression of chronic kidney injury by transcriptional induction of ALK3, the principal mediator of antifibrotic and proregenerative bone morphogenetic protein-signaling (BMP-signaling) responses. We further report that ARNT expression itself is controlled by the FKBP12/YY1 transcriptional repressor complex and that disruption of such FKBP12/YY1 complexes by picomolar FK506 at subimmunosuppressive doses increases ARNT expression, subsequently leading to homodimeric ARNT-induced ALK3 transcription. Direct targeting of FKBP12/YY1 with in vivo morpholino approaches or small molecule inhibitors, including GPI-1046, was equally effective for inducing ARNT expression, with subsequent activation of ALK3-dependent canonical BMP-signaling responses and attenuated chronic organ failure in models of chronic kidney disease, and also cardiac and liver injuries. In summary, we report an organ-protective mechanism that can be pharmacologically modulated by immunophilin ligands FK506 and GPI-1046 or therapeutically targeted by in vivo morpholino approaches.
Pharmacological induction of hypoxia-inducible transcription factor ARNT attenuates chronic kidney failure
Results
Low-dose FK506 protects the kidney from chronic organ injury dependent on enhanced ALK3 signaling. Based on previous regimens (5-9), we administered low-dose FK506 (0.02, 0.075, and 0.2 mg/kg orally per day) to mice starting 1 day prior to challenge with unilateral ureteral obstruction (UUO) ( Figure 1A ). We also included standard immunosuppressive dose FK506 (5.0 mg/kg orally per day) and cyclosporine A (CsA) (10 mg/kg orally per day), an alternative CNI that acts independently of FKBPs (15, 16) The panels show representative photomicrographs of kidney sections stained with periodic acid-Schiff (PAS) and sections immunolabeled with primary antibodies against collagen-1. Scale bars: 50 μm (PAS, MTS); 25 μm (collagen-1). MTS, Masson's trichrome stain. (C) Tubular damage at day 10 after UUO was semiquantitatively scored using PAS-stained kidney sections. 0, healthy; 1, mild; 2, moderate; 3, severe. n = 6/group. Data are presented as mean ± SD. ***P < 0.001; # P < 0.0001, 1-way ANOVA with Bonferroni's post hoc analysis. (D) Graph summarizes average means of relative tubulointerstitial fibrosis 3, 7, and 10 days after UUO. n = 6/group. Data are presented as mean ± SD. # P < 0.0001, 1-way ANOVA with Bonferroni's post hoc analysis. (E) In mice receiving FK506, areas positive for collagen-1 were assessed. n = 6/group. Data are presented as mean ± SD. # P < 0.0001, 1-way ANOVA with Bonferroni's post hoc analysis. (F) FK506 concentrations were measured in whole blood samples of UUO mice receiving either vehicle buffer or FK506 (0.02, 0.075, 0.2 mg/kg orally per day, respectively) using colorimetric ELISA measurements compared with standards. n = 6/group. Data are presented as aligned dot plots with means. GO:0071772 and GO:0071773, Supplemental Figure 2A and Supplemental Table 1 ) (17, 18) , including the prototypical type I BMP receptor ALK3 (synonym, type I BMP receptor serine/threonine kinase, BMPR1A). Because multiple independent studies dem- Figure  4A ), conditional Yy1 depletion in TECs resulted in enhanced Alk3 transcription, protection from tubular injury, and renal fibrogenesis (Figure 4 , B-G). When Yy1 was depleted in TECs, administration of FK506 had no additive effects (Figure 4 , B-G), indicating that FK506-mediated antifibrotic and proregenerative efficacy is dependent on presence and modulation of YY1 signaling in TECs.
ARNT causally links disruption of FKBP12/YY1 complexes to increased ALK3 transcription. In control experiments in which cycloheximide (CHX) (10 μg/ml) was added to cell-culture medium to block protein translation, FK506 failed to induce Alk3 transcription and canonical BMP-signaling responses (nuclear p-Smad1/5/8, Figure 5 , A-C). These observations suggested that de novo translation of yet-unknown mediator(s) is required to induce Alk3 transcription after release from Fkbp12/Yy1 transcriptional repressor complexes, supported by absence of putative Yy1-binding motifs within the Alk3 proximal promoter region (31) . By using an unbiased, array-based approach and computational prediction of putative transcriptional factor binding sites in human These observations were further supported by transcriptional expression data sets with robust induction of ARNT and enrichment of ARNT-regulated genes induced in response to FK506 (GEO GSE5258, Supplemental Figure 3H and Supplemental Table  2 ) (17, 18, 28) . To further explore a causal link between Fkbp12/ Yy1 complex disruption and increased Alk3 transcription, we performed Arnt ChIP PCR using antibodies to Yy1 for immunoprecipitation (IP: Yy1). ChIP demonstrated binding of Yy1 to its putative motif within the Arnt proximal promoter in cultured TECs that had been maintained in control media without FK506 (with low Alk3 expression levels, Figure 5I (27) .
YY1 links immunophilin FKBP12 and ALK3 transcription in response to FK506. We next aimed to gain insights into the molecular mechanisms underlying observed increased Alk3 transcription within tubular epithelial cells (TECs) upon low-dose FK506 administration. We exposed murine TECs to different concentrations of FK506 ranging from standard nanomolar dosages used for immunosuppression in transplant patients (2-200 nM) down to picomolar concentrations (0.02-0.2 nM) reflecting FK506 regimens, which we had used in our murine studies. FK506 induced optimal Alk3 transcription and p-Smad1/5/8 accumulation at concentrations from 0.2 nM to 2 nM, whereas higher concentrations had no further enhancing effects ( Figure 3 Figure 3D ). Because we did not detect direct interaction of Fkbp12 and Alk3 ( Figure 3E and Supplemental Figure 3G ) (8) and Fkbp12 has no DNA binding properties itself, we hypothesized that Fkbp12 alters Alk3 transcription by interacting with a to-be-determined transcriptional regulator and that FK506 affects Alk3 expression via interaction with this Fkbp12/transcriptional regulator complex. We identified enrichment of genes regulated by Yin Yang 1 (YY1) in response to FK506 (GEO GSE5258, Supplemental Figure 3H and Supplemental Table 2 ) (17, 18, 28) , an established FKBP12-interacting protein (Supplemental Figure 3I) (29) . YY1 is a GLI-Krüppel family member known to regulate transcription based on its interaction with adapter proteins, including FKBPs (30) . Coimmunoprecipitation using antibodies to Yy1 (IP: Yy1) revealed direct interaction of Yy1 and Fkbp12 in cultured TECs, while such Fkbp12/Yy1 interaction was not detectable when FK506 was added to culture medium ( Figure 3F and Supplemental Figure 3J (Figure 9, A and B) . Based on our previous regimen, we next administered GPI-1046 (10 mg/kg subcutaneously per day) 1 day prior to UUO challenge ( Figure 9C ) (37) . Nonimmunosuppressive GPI-1046 effectively induced intrarenal Arnt and Alk3 transcription and BMP-signaling responses and protected from tubular injury and renal fibrogenesis ( Figure 9 , D-K), further supporting the idea that immunophilin Fkbp12 is specifically involved in modulating intrarenal Arnt/Alk3 signaling and protection from injury independently of calcineurin modulation or immunosuppressive properties. This was further confirmed by uniform immune cell infiltration in cohorts of mice administered either picomolar FK506 or nonimmunosuppressive GPI-1046 not affecting intrarenal NFAT signaling (Supplemental Figure 7 , A-C). To determine whether administration of FK506 or GPI-1046 was also effective in attenuating CKD progression when administration is initiated after manifestation of kidney injury, we next administered FK506 or GPI-1046 3 days after challenging with UUO (0.2 mg/kg or 30 mg/kg orally per day, respectively, Figure 10A ). Both FK506 and small molecule Fkbp12 inhibitor GPI-1046 were equally effective in inducing intrarenal Arnt and Alk3 transcription, associated with attenuated tubular injury and renal fibrogenesis ( Figure 10 , B-H).
Selective targeting of FKBP12 protects from chronic injury in the heart and liver. Effectiveness of FK506 had been documented in various parenchymal organs (4-12), in line with transcriptional Arnt induction present in the kidney (confirming previous results) and also in the heart, brain, spinal cord, skin, liver, lung, and intestine in response to FK506 or GPI-1046 (0.2 mg/kg or 30 mg/kg orally per day, respectively; Figure 11 , A and B). Based on robust Arnt induction observed in the heart and liver (Supplemental Figure 8, A and B) , we next analyzed the presence of an Fkbp12/Yy1/Arnt/Alk3 signaling axis in rodent models of cardiac fibrosis after continuous minipump delivery of angiotensin II (AT II) and carbon tetrachloride-induced (CCl 4 -induced) liver failure (23, 38) . Fkbp12 and Yy1 were detectable in chronically injured hearts and livers (Supplemental Figure 9 , A-F), suggesting that repressive Fkbp12/Yy1 complexes were equally present. To elucidate whether the identified Fkbp12/Yy1/Arnt/ Alk3 signaling axis could be equally targeted to protect from chronic heart failure and fibrosis, we next administered GPI-1046 (10 mg/ kg subcutaneously per day) 1 day prior to administration of AT II ( Figure 11C ). GPI-1046 was equally effective in induction of Alk3-dependent canonical BMP-signaling responses and protection from fibrogenesis in the heart (Figure 11 , D-K, and Supplemental Figure  9 , G-J). These results were also confirmed in mice challenged with CCl 4 ( Figure 12A ). GPI-1046 equally induced Alk3-dependent signaling responses and protected from chronic liver failure (Figure 12 Figure 6L ). We did not detect Hif1α, Hif2α, or Ahr as constituents of Arnt dimers, further suggesting that transcriptional responses to FK506 in TECs are mediated by homodimerized Arnt (Figure 6L ) (32) . Alk3 ChIP-PCR revealed increased Arnt binding to its respective homodimer motif upon exposure to FK506 (associated with enhanced Arnt homodimers and enhanced Alk3 transcription; Figure 6M ) (33, 34) . Transcriptional Alk3 induction was further confirmed by reporter assays, as Arnt overexpression effectively induced Alk3 proximal promoter activity (Alk3 WT , Figure 6N ). In contrast, Arnt failed to induce Alk3 transcription when the Arnt homodimer target sequence was disrupted (CACGTG to TATATA, Alk3 mut , Figure 6N ). These findings in cultured TECs were further confirmed by increased Arnt levels in γGT BMP-signaling responses in kidney allografts matched for comparable kidney function, chronic tubular injury, and extent of interstitial fibrosis (Supplemental Figure 11 , A-F, and Supplemental Table 7 ). Immunolabeling confirmed the presence of FKBP12 and YY1 in all allografts ( Figure 13C ), while enhanced ARNT and ALK3 transcription was present in kidney biopsies of patients on an FK506-based immunosuppressive regimen as compared with those receiving CsA ( Figure 13 , C-H).
Discussion
Here, we report a renoprotective mechanism that is controlled by the transcription factor ARNT, which effectively inhibits progression of chronic kidney injury by inducing ALK3 transcription. We further report that ARNT expression itself is controlled by the FKBP12/YY1 transcriptional repressor complex (Supplemental Figure 12A ) and that disruption of such FKBP12/YY1 complexes ings, FKBP12 and YY1 were equally detectable in human pathologies, including chronically injured kidneys, livers, and lungs, as prerequisites of identified organ protection mediated by FK506 (Supplemental Figure 10 , A-C, and Supplemental Table 6 ). To elucidate whether modulation of an FKBP12/YY1/ARNT/ALK3 signaling axis was not only limited to mice, but was similarly effective in humans, we next exposed human TECs to FK506 and analyzed efficacy to induce protective ARNT. Exposure of human TEC cultures to previous established picomolar FK506 equally induced ARNT transcription and ALK3 ( Figure 13, A and  B) . Because FK506 has been in clinical use for decades to prevent rejection of kidney transplants at high immunosuppressive doses (with well-established adverse toxicity likely masking beneficial effects) and not at the low doses at which we observed optimal renoprotection in rodents, we focused in our analysis on the induction of ARNT expression and subsequent ALK3-mediated thermore, kidney allografts of patients on an FK506-based immunosuppressive regimen displayed enhanced intrarenal ARNT and ALK3 transcription as compared with allografts of patients on CsA (Supplemental Figure 14 , B and C) (44) . Organ protection by the FKBP12/YY1/ARNT/ALK3 signaling axis is in line with extensive literature on 2 previously unconnected lines of research, as several studies have highlighted the efficacy of low-dose FK506 administration to protect against acute experimental injuries, including those of the kidney, heart, and liver (5-7), and multiple preclinical studies established beneficial effects of ALK3-mediated BMP signaling in these organs (19) (20) (21) (22) (23) .
At the mechanistic level, we report that the homodimerization of ARNT is critical to eliciting its function in inducing ALK3 transcription. ARNT in general is a member of the PAS domain by picomolar FK506 at subimmunosuppressive doses, small molecule FKBP12 inhibitor GPI-1046, or direct targeting of FKBP12/ YY1 using VMOs increases ARNT levels (Supplemental Figure  12B) . Subsequent activation of ALK3-dependent canonical BMPsignaling responses by ARNT homodimer formation (independently of HIF1α or AHR) attenuates chronic organ failure in models of chronic kidney, cardiac, and liver injuries (Supplemental Figure  12, C and D) . The identified FKBP12/YY1/ARNT/ALK3 signaling axis is supported by mining of public expression profiling databases in various organs: in the context of the kidney, an inverse correlation between intrarenal ALK3 expression and FKBP12/YY1 was confirmed by several array data sets performed in different renal pathologies (Supplemental Figure 13, A-F) (39-44) , confirmed in microdissected renal tubules (Supplemental Figure 14A) (45) . Fur- genomic E-box motifs (32) . A unique function of homodimeric ARNT as compared with heterodimeric ARNT is supported by recent studies that established the palindromic E-box motif CACGTG as a critical binding site for ARNT homodimers, while family, which is predominantly known to heterodimerize with other PAS family members to form heterodimeric transcription factors, classically with an α subunit of HIF or the dioxin receptor AHR to mediate hypoxia or xenobiotic responses by targeting correlation between ARNT and FKBP12/YY1 in multiple organ systems, including renal, cardiovascular, and digestive tissues, confirming our findings (GEO GSE3526, Supplemental Table 8 ) (48) . In this context, previous reports implicate activation of a YY1 signaling axis as detectable in renal, cardiac, hepatic, and pulmonary pathologies and show that YY1 depletion protects from chronic organ failure (49) (50) (51) . It is tempting to speculate that modulation of the newly identified FKBP12/YY1/ARNT/ALK3 signaling axis may be a promising target in chronic failure of multiple organ systems. In this regard, low-dose FK506 has already entered clinical testing (ClinicalTrials.gov NCT01647945) and shown promise in ARNT heterodimers bind to asymmetric E-box motifs in hypoxic/ xenobiotic response elements (33, 34) . As ARNT homodimerization potentially provides another therapeutic target, additional research is warranted to explore the underlying mechanisms. In this regard, our studies suggest that the fate decision of homodimerization over heterodimerization is in part regulated by intracellular ARNT levels controlled by FKBP12/YY1 transcriptional repressor complexes. This is supported by array data sets confirming transcriptional ARNT induction when YY1 was depleted (Supplemental Figure 14 , D and E) (46) and binding of YY1 repressor to the ARNT proximal promoter (47) . In addition, clustering of transcriptome array data sets revealed inverse why protective activity of FK506 in interventional therapeutic regimens has remained elusive thus far. Efficacy of the specific FKBP12 inhibitor GPI-1046 in protecting and attenuating disease progression in kidney, heart, and liver validated observed efficacy of FK506 and also provided a more specific tool from a translational perspective. Thus, we speculate that pharmacologic modulation of ARNT homodimerization and FKBP12/YY1 complexes may have translational potential for organ protection in the future.
pulmonary arterial hypertension patients in inducing protective BMP-signaling responses (52) . Observed beneficial efficacy of FK506 was counterintuitive at first sight because decades of use as an immunosuppressant upon kidney transplantation had revealed its CNI nephrotoxicity, thereby limiting its clinical use (14) . However, our studies established that FK506-induced organ protection is independent of CNI activity, as it is achieved at picomolar doses far below the nanomolar immunosuppressive regimens. Hence, we provide mechanistic evidence for Statistics. The numbers of individual mice and independent experiments are indicated in the corresponding figure legends. For single-group comparison, 2-tailed Student's t test was used to determine statistical significance. One-way ANOVA with Bonferroni's post hoc analysis was used for multiple comparisons of samples to determine statistical significance. Linear regression was performed comparing indicated pairs of parameters, and r 2 and P values are indicated in the corresponding graphs. Statistical significance was calculated with Prism 5 software (GraphPad) and defined as P < 0.05. Study approval. All animal studies were carried out with the approval of the Landesamt für Verbraucherschutz und Lebensmittelsicherheit (LAVES, Oldenburg, Germany) and the University Medical Center Göttingen. The use of parts of human specimens for research purposes was approved by the Ethics Committee of the University Medical Center Göttingen. All patients gave informed consent, and all samples were deidentified. A pathologist assessed for the presence of disease. Clinical data are presented in Supplemental Tables 6 and 7 .
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